Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer

Future Oncology

Volumn 8, Issue 3, 2012, Pages 231-237

  Amato, Robert J ^a   Stepankiw, Mika ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

cancer vaccines; colorectal cancer; MVA 5T4; prostate cancer; renal cell carcinoma; TroVax

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; MODIFIED VACCINIA VIRUS ANKARA 5T4 VACCINE; PLACEBO; RECOMBINANT ALPHA INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 2; SUNITINIB;

CANCER GRADING; CANCER IMMUNOTHERAPY; COLORECTAL CANCER; DRUG DOSE ESCALATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEVER; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; KIDNEY CANCER; LOW DRUG DOSE; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; UNSPECIFIED SIDE EFFECT;

CANCER VACCINES; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; DRUG DELIVERY SYSTEMS; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; MALE; MEMBRANE GLYCOPROTEINS; PROSTATIC NEOPLASMS; VACCINATION; VACCINIA VIRUS;

EID: 84858392112     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.7     Document Type: Review

References (26)

1. Amato RJ. 5T4-modified vaccinia Ankara: Progress in tumor-associated antigen-based immunotherapy. Expert Opin Biol. Ther. 7(9), 1463-1469 (2007)
2. Harrop R, John J, Carrol MW. Recombinant viral vectors: Cancer vaccines. Adv. Drug Delivery Rev. 588, 931-947 (2006
3. Harrop R, Carrol MW. Viral vectors for cancer immunotherapy. Front. Biosci. 11, 804-817 (2006
4. Starzynska T, Marsh P, Schofield P et al. Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma. Br. J. Cancer 69, 899-902 (1994
5. Griffiths RW, Gilham DR, Dangoor A et al. Expression of the 5T4 oncofoetal antigen in renal cell carcinoma: A potential target for T-cell-based immunotherapy. Br. J. Cancer 93(6), 670-677 (2005
6. Barrow KM, Ward CM, Rutter J, Ali S, Stern PL. Embryonic expression of murine 5T4 oncofetal antigen is associated with morphogenetic events at implantation and in developing epithelia. Dev. Dyn. 233(4), 1535-1545 (2005
7. Hole N, Stern PL. A 72 kD trophoblast glycoprotein defined by a monoclonal antibody. Br. J. Cancer 57, 237-246 (1988
8. Southall P, Boxer G, Bagshaw K et al. Immunological distribution of 5T4 antigen in normal and malignant tissues. Br. J. Cancer 61, 89-95 (1990
9. Southgate TD, McGinn OJ, Castro FV et al. CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glycoprotein in mouse embryonic cells. PLoS ONE 5(4), e9982 (2010
10. Sutter G, Moss B. Non-replicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl Acad. Sci. USA 89, 10847-10851 (1992
11. Harrop R, Ryan, MG, Myers KA et al. Active treatment of murine tumors with a highly attenuated vaccinia virus expressing the tumor associated antigen 5T4 (TroVax) is CD4+ T cell dependent and antibody mediated. Cancer Immunol. Immunother. 55(9), 1081-1090 (2006
12. Mulryan K, Ryan MG, Myers KA et al. Attenuated recombinant vaccinia virus expressing oncofetal antigen (tumor-associated antigen) 5T4 induces active therapy of established tumors. Mol. Cancer Ther. 1, 1129-1137 (2002
13. Harrop R, Connolly NB, Redchenko I et al. Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: A Phase I/II trial. Clin. Cancer Res. 12(11), 3416-3424 (2006
14. Harrop R, Drury N, Shingler W et al. Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses. Cancer Immunol. Immunother. 57(7), 977-986 (2008
15. Harrop R, Drury N, Shingler W et al. Vaccination of colorectal cancer patients with modified vaccinia ankara encoding the tumor antigen 5T4 (TroVax) given alongside chemotherapy induces potent immune responses. Clin. Cancer Res. 13(15 Pt 1), 4487-4494 (2007
16. Elkord E, Dangoor A, Burt DJ et al. Immune evasion mechanisms in colorectal cancer liver metastasis patients vaccinated with TroVax (MVA-5T4). Cancer Immunol. Immunother. 58(10), 1657-1667 (2009
17. Hawkins RE, MacDermott C, Shablak A et al. Vaccination of patients with metastatic renal cancer with modified vaccinia Ankara encoding the tumor antigen 5T4 (TroVax) given alongside interferon-a. J. Immunother. 3(4), 424-429 (2009
18. Amato RJ, Shingler W, Goonewardena M et al. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): A Phase 2 trial. J. Immunother. 32(7), 765-772 (2009). This study demonstrated that MVA-5T4 was well tolerated both alone and in combination, and induced an increased immune response in patients.
19. Kaufman HL, Taback B, Sherman W et al. Phase II trial of modified vaccinia Ankara (MVA) virus expressing 5T4 and high dose interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma. J. Transl Med. 7, 2 (2009). MVA-5T4 was safely combined with high-dose IL-2.
20. Amato R, Shingler W, Naylor S et al. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering tumor antigen 5T4 (TroVax) administered with interleukin 2: A Phase II trial. Clin. Cancer Res. 14(22), 7504-7510 (2008). MVA-5T4 plus IL-2 was found to be well tolerated and to induce an immune response in renal cell cancer patients, leading to the Phase III TRIST clinical trial.
21. Amato RJ, Drury N, Naylor S et al. Vaccination of prostate cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax): A Phase 2 trial. J. Immunother. 31(6), 577-585 (2008
22. Amato RJ, Hawkins RE, Kaufman HL et al. Vaccination of metastatic renal cancer patients with MVA-5T4: A randomized, double-blind, placebo-controlled Phase III study. Cancer Res. 16(22), 5539-5547 (2010). Phase III trial confirming that MVA-5T4 produced immune response activity, and established the need for improved patient selection to maximize clinical benefit.
23. Motzer RJ, Hutson TE, Tomczak P et al. Sunitinib versus interferon-a in metastatic renal-cell carcinoma. N. Engl. J. Med. 256(2), 115-124 (2007
24. Huang S, Houston P. Targeting mTOR signaling for cancer therapy. Curr. Opin Pharmacol. 3(4), 371-377 (2003
25. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon-a, or both for advanced renal-cell carcinoma. N. Engl. J. Med. 356(22), 2271-2281 (2007)
26. Harrop R, Shingler WH, McDonald M et al. MVA-5T4-induced immune responses are an early marker of efficacy in renal cancer patients. Cancer Immunol. Immunother. 60, 829-837 (2011)